Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
$4.15
+2.2%
$5.92
$3.99
$28.41
$375.58M2.151.80 million shs2.75 million shs
Guardant Health, Inc. stock logo
GH
Guardant Health
$39.17
+3.1%
$43.11
$20.14
$52.92
$4.85B1.492.14 million shs1.83 million shs
RadNet, Inc. stock logo
RDNT
RadNet
$56.68
+0.1%
$53.07
$45.00
$93.65
$4.25B1.46686,228 shs456,091 shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$27.97
+3.0%
$30.32
$19.73
$47.32
$2.19B2.14894,425 shs843,609 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
+2.22%-11.51%-29.90%-72.48%-83.76%
Guardant Health, Inc. stock logo
GH
Guardant Health
+3.08%-2.00%-18.90%-9.31%+53.49%
RadNet, Inc. stock logo
RDNT
RadNet
+0.12%-5.78%+12.77%-4.47%-3.18%
Veracyte, Inc. stock logo
VCYT
Veracyte
+2.98%-2.92%-13.22%-21.28%+34.47%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
3.2467 of 5 stars
3.92.00.00.02.30.82.5
Guardant Health, Inc. stock logo
GH
Guardant Health
4.6637 of 5 stars
4.52.00.04.34.12.50.6
RadNet, Inc. stock logo
RDNT
RadNet
3.4019 of 5 stars
2.71.00.04.63.52.50.0
Veracyte, Inc. stock logo
VCYT
Veracyte
4.0477 of 5 stars
4.41.00.04.33.50.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
1.86
Reduce$15.00261.45% Upside
Guardant Health, Inc. stock logo
GH
Guardant Health
3.05
Buy$52.3233.57% Upside
RadNet, Inc. stock logo
RDNT
RadNet
3.40
Buy$69.7523.06% Upside
Veracyte, Inc. stock logo
VCYT
Veracyte
2.70
Moderate Buy$40.9046.23% Upside

Current Analyst Ratings Breakdown

Latest RDNT, VCYT, FTRE, and GH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
5/14/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/14/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.00
5/14/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$7.00 ➝ $5.00
5/13/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$6.00 ➝ $5.00
5/8/2025
Veracyte, Inc. stock logo
VCYT
Veracyte
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$49.00 ➝ $42.00
5/8/2025
Veracyte, Inc. stock logo
VCYT
Veracyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$51.00 ➝ $41.00
5/6/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$50.00 ➝ $60.00
5/5/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/5/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$52.00 ➝ $57.00
5/2/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$7.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
$2.69B0.14$0.66 per share6.28$19.58 per share0.21
Guardant Health, Inc. stock logo
GH
Guardant Health
$774.00M6.27N/AN/A$1.34 per share29.23
RadNet, Inc. stock logo
RDNT
RadNet
$1.87B2.27$3.01 per share18.81$11.79 per share4.81
Veracyte, Inc. stock logo
VCYT
Veracyte
$463.39M4.73$0.06 per share442.29$14.30 per share1.96
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
-$3.40M-$8.79N/A3.241.78-10.99%2.00%0.80%8/11/2025 (Estimated)
Guardant Health, Inc. stock logo
GH
Guardant Health
-$479.45M-$3.39N/AN/AN/A-59.05%-19,157.20%-25.96%8/6/2025 (Estimated)
RadNet, Inc. stock logo
RDNT
RadNet
$3.04M-$0.43N/A106.94N/A-0.25%4.29%1.45%8/5/2025 (Estimated)
Veracyte, Inc. stock logo
VCYT
Veracyte
-$74.40M$0.41N/A38.85N/A-2.18%3.02%2.80%8/5/2025 (Estimated)

Latest RDNT, VCYT, FTRE, and GH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
-$0.07$0.02+$0.09-$6.25$609.63 million$651.30 million
4/30/2025Q1 2025
Guardant Health, Inc. stock logo
GH
Guardant Health
-$0.57-$0.49+$0.08-$0.77$189.91 million$203.47 million
3/3/2025Q4 2024
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
$0.36$0.18-$0.18-$0.68$703.22 million$697.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
N/AN/AN/AN/AN/A
Guardant Health, Inc. stock logo
GH
Guardant Health
N/AN/AN/AN/AN/A
RadNet, Inc. stock logo
RDNT
RadNet
N/AN/AN/AN/AN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
0.74
1.18
1.18
Guardant Health, Inc. stock logo
GH
Guardant Health
N/A
6.22
5.85
RadNet, Inc. stock logo
RDNT
RadNet
0.89
2.16
2.16
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A
5.08
4.79

Institutional Ownership

CompanyInstitutional Ownership
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
N/A
Guardant Health, Inc. stock logo
GH
Guardant Health
92.60%
RadNet, Inc. stock logo
RDNT
RadNet
77.90%
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A

Insider Ownership

CompanyInsider Ownership
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
0.12%
Guardant Health, Inc. stock logo
GH
Guardant Health
6.10%
RadNet, Inc. stock logo
RDNT
RadNet
5.12%
Veracyte, Inc. stock logo
VCYT
Veracyte
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
18,00090.50 million89.59 millionOptionable
Guardant Health, Inc. stock logo
GH
Guardant Health
1,790123.89 million116.76 millionNot Optionable
RadNet, Inc. stock logo
RDNT
RadNet
8,97075.03 million70.24 millionOptionable
Veracyte, Inc. stock logo
VCYT
Veracyte
79078.32 million76.49 millionOptionable

Recent News About These Companies

Veracyte: Upgrading To Neutral
Comparing Veracyte (NASDAQ:VCYT) and Grail (NASDAQ:GRAL)
William Blair Predicts Veracyte's Q2 Earnings (NASDAQ:VCYT)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Fortrea stock logo

Fortrea NASDAQ:FTRE

$4.15 +0.09 (+2.22%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$4.15 +0.00 (+0.10%)
As of 05/27/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Guardant Health stock logo

Guardant Health NASDAQ:GH

$39.17 +1.17 (+3.08%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$39.32 +0.14 (+0.37%)
As of 04:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

RadNet stock logo

RadNet NASDAQ:RDNT

$56.68 +0.07 (+0.12%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$58.00 +1.32 (+2.33%)
As of 05/27/2025 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

Veracyte stock logo

Veracyte NASDAQ:VCYT

$27.97 +0.81 (+2.98%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$27.97 0.00 (0.00%)
As of 05/27/2025 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.